Efficacy and safety of favipiravir plus interferon‐beta versus lopinavir/ritonavir plus interferon‐beta in moderately ill patients with COVID‐19: A randomized clinical trial

Favipiravir (FVP), lopinavir/ritonavir (LPV/RTV), and interferon‐beta (INF‐beta) are considered as potential treatments for COVID‐19. We examined the efficacy and safety of FVP and INF‐beta compared to LPV/RTV and INF‐beta combinations for the treatment of SARS‐CoV‐2. It was a single‐center randomiz...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of medical virology 2022-07, Vol.94 (7), p.3184-3191
Hauptverfasser:	Hassaniazad, Mehdi, Farshidi, Hossein, Gharibzadeh, Abdollah, Bazram, Ali, Khalili, Elham, Noormandi, Afsaneh, Fathalipour, Mohammad
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Amides Antiretroviral drugs antiviral agents Antiviral drugs Clinical trials COVID-19 COVID-19 - drug therapy Humans Interferon Interferon-beta Iran Lopinavir Lopinavir - adverse effects Mortality Patients Pyrazines Randomization Ritonavir Ritonavir - adverse effects Safety SARS-CoV-2 SARS‐coronavirus Severe acute respiratory syndrome coronavirus 2 Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!